Aliases & Classifications for C3 Glomerulopathy

MalaCards integrated aliases for C3 Glomerulopathy:

Name: C3 Glomerulopathy 24 25
C3 Glomerulonephritis 25 29 73
C3g 24 25
Membranoproliferative Glomerulonephritis, Type Ii 73
Membranoproliferative Glomerulonephritis Type Ii 25
Glomerulonephritis with Dominant C3 24
Dense Deposit Disease 25
Ddd/mpgnii 25
Ddd 25

External Ids:

Summaries for C3 Glomerulopathy

Genetics Home Reference : 25 C3 glomerulopathy is a group of related conditions that cause the kidneys to malfunction. The major features of C3 glomerulopathy include high levels of protein in the urine (proteinuria), blood in the urine (hematuria), reduced amounts of urine, low levels of protein in the blood, and swelling in many areas of the body. Affected individuals may have particularly low levels of a protein called complement component 3 (or C3) in the blood.

MalaCards based summary : C3 Glomerulopathy, also known as c3 glomerulonephritis, is related to dense deposit disease and hemolytic uremic syndrome, atypical 1. An important gene associated with C3 Glomerulopathy is C3 (Complement C3), and among its related pathways/superpathways are Creation of C4 and C2 activators and Complement and coagulation cascades. The drugs Daratumumab and Immunoglobulin A have been mentioned in the context of this disorder. Affiliated tissues include kidney, b cells and testes.

GeneReviews: NBK1425

Related Diseases for C3 Glomerulopathy

Graphical network of the top 20 diseases related to C3 Glomerulopathy:



Diseases related to C3 Glomerulopathy

Symptoms & Phenotypes for C3 Glomerulopathy

Drugs & Therapeutics for C3 Glomerulopathy

Drugs for C3 Glomerulopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Daratumumab Approved Phase 2 945721-28-8
2 Immunoglobulin A Phase 2
3 Antibodies Phase 2
4 Immunoglobulins Phase 2
5 Antibodies, Monoclonal Phase 2
6 Antigen-Antibody Complex Phase 2
7 Complement C3 Phase 1
8 Complement Inactivating Agents Phase 1
9 Complement System Proteins Phase 1
10 Immunosuppressive Agents Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Controlled Trial Evaluating Avacopan in C3 Glomerulopathy Recruiting NCT03301467 Phase 2 Avacopan;Avacopan Matching Placebo
2 Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Recruiting NCT02682407 Phase 2
3 A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G) Recruiting NCT03369236 Phase 2 ACH-0144471;Placebo
4 A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Recruiting NCT03459443 Phase 2 ACH-0144471
5 Daratumumab in Treatment of PGNMID and C3 GN Recruiting NCT03095118 Phase 2 Daratumumab
6 A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN Recruiting NCT03124368 Phase 2 ACH-0144471
7 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Recruiting NCT03453619 Phase 2 APL-2
8 First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers Completed NCT03316521 Phase 1 AMY-101
9 Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease Terminated NCT01791686 Phase 1 CDX-1135
10 TP10 Use in Patients With C3 Glomerulopathy (C3G) Withdrawn NCT02302755 Phase 1 TP10

Search NIH Clinical Center for C3 Glomerulopathy

Genetic Tests for C3 Glomerulopathy

Genetic tests related to C3 Glomerulopathy:

# Genetic test Affiliating Genes
1 C3 Glomerulonephritis 29

Anatomical Context for C3 Glomerulopathy

MalaCards organs/tissues related to C3 Glomerulopathy:

41
Kidney, B Cells, Testes

Publications for C3 Glomerulopathy

Articles related to C3 Glomerulopathy:

(show top 50) (show all 103)
# Title Authors Year
1
Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft. ( 29724174 )
2018
2
Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. ( 29326307 )
2018
3
Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome. ( 29517501 )
2018
4
Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy? ( 29808447 )
2018
5
C3 glomerulopathy associated with monoclonal IgA is a distinct subtype. ( 29729982 )
2018
6
Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. ( 29429752 )
2018
7
Genetic analysis of the complement pathway in C3 glomerulopathy. ( 29566171 )
2018
8
C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. ( 29310824 )
2018
9
C3 glomerulopathy in cystic fibrosis: a case report. ( 29592796 )
2018
10
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. ( 29948306 )
2018
11
Recurrent postinfectious glomerulonephritis: an unusual evolution compatible with C3 glomerulopathy. ( 29477994 )
2018
12
C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction. ( 29594148 )
2018
13
C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab. ( 29370420 )
2018
14
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. ( 29500241 )
2018
15
An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. ( 29588430 )
2018
16
A case of recurrent proliferative glomerulonephritis with monoclonal IgG deposits or de novo C3 glomerulonephritis after kidney transplantation. ( 29968411 )
2018
17
Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily. ( 29895552 )
2018
18
Treating C3 glomerulopathy with eculizumab. ( 29329521 )
2018
19
C3 glomerulopathy in NLRP12-related autoinflammatory disorder: case-based review. ( 29951964 )
2018
20
C3 glomerulonephritis and thrombotic microangiopathy of renal allograft after pulmonary infection in a male with concomitant two complement factor I gene variations: a case report. ( 29940891 )
2018
21
Three cases of monoclonal gammopathy of renal significance after kidney transplantation. De novo C3 glomerulopathy. ( 29914760 )
2018
22
Acquired partial lipodystrophy and C3 glomerulopathy: Dysregulation of the complement system as a common pathogenic mechanism. ( 29279276 )
2017
23
C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. ( 28838767 )
2017
24
C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant. ( 28356669 )
2017
25
Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. ( 28069603 )
2017
26
C3 glomerulopathy and eculizumab: a report on four paediatric cases. ( 28236143 )
2017
27
Case report: C3 glomerulopathy advancing atypical hemolytic uremic syndrome. ( 29150227 )
2017
28
Atypical Plasmacytic Proliferation in a Case of C3 Glomerulopathy: Pathophysiology Demystified. ( 28210641 )
2017
29
Crescentic C3 glomerulopathy with acquired partial lipodystrophy: An unusual cause of rapidly progressive renal failure. ( 28631660 )
2017
30
Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. ( 28096309 )
2017
31
Multimodal imaging of retinal pigment epithelial detachments in patients with C3 glomerulopathy: case report and review of the literature. ( 29166869 )
2017
32
A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. ( 28729035 )
2017
33
Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective? ( 28700996 )
2017
34
Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies. ( 28573137 )
2017
35
Immunosuppressive Treatment in C3 Glomerulopathy: Time to Reconsider Our Approach. ( 28700984 )
2017
36
C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy. ( 28139294 )
2017
37
C3 glomerulopathy. ( 28357053 )
2017
38
Dominant C3 glomerulopathy: new roles for an old actor in renal pathology. ( 29151252 )
2017
39
Characterization of C3 in C3 glomerulopathy. ( 27507892 )
2016
40
C3 glomerulopathy and current dilemmas. ( 27878657 )
2016
41
Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy. ( 26924054 )
2016
42
Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies. ( 27356907 )
2016
43
Retinal disease in the C3 glomerulopathies and the risk of impaired vision. ( 26915021 )
2016
44
Complement inhibition in C3 glomerulopathy. ( 27402056 )
2016
45
Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy. ( 27274823 )
2016
46
Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. ( 26660535 )
2016
47
C3 glomerulonephritis in multiple myeloma: A case report and literature review. ( 27631242 )
2016
48
Kidney transplant outcomes in familial C3 glomerulopathy. ( 27274824 )
2016
49
Overview of C3 Glomerulopathy. ( 27200326 )
2016
50
C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome. ( 27994856 )
2016

Variations for C3 Glomerulopathy

Expression for C3 Glomerulopathy

Search GEO for disease gene expression data for C3 Glomerulopathy.

Pathways for C3 Glomerulopathy

GO Terms for C3 Glomerulopathy

Cellular components related to C3 Glomerulopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.55 C3 CFB CFHR1 CFHR5 CFP
2 protein-containing complex GO:0032991 9.43 C3 CFHR1 CFHR5
3 extracellular space GO:0005615 9.35 C3 CFB CFHR1 CFHR3 CFP
4 blood microparticle GO:0072562 8.92 C3 CFB CFHR1 CFHR3

Biological processes related to C3 Glomerulopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.54 C3 CFB CFP
2 complement activation GO:0006956 9.46 C3 CFB CFHR1 CFP
3 regulation of complement activation GO:0030449 9.35 C3 CFB CFHR1 CFHR5 CFP
4 negative regulation of protein binding GO:0032091 9.32 CFHR1 CFHR5
5 positive regulation of cytolysis GO:0045919 9.26 CFHR1 CFHR5
6 complement activation, alternative pathway GO:0006957 8.92 C3 CFB CFHR5 CFP

Sources for C3 Glomerulopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....